← Back

Sightera Biosciences

Antwerp, Belgium

pre-seed$3.3M raisedFreshly fundedhealthtechdeeptechbiotech

◆ Total Raised

$3.3M

◆ Stage

pre-seed

◆ Location

Antwerp, Belgium

◆ Founded

2024

◆ Team size

1-10

◆ Links

Website ↗LinkedIn ↗

◆ About Sightera Biosciences

Patient-derived AI drug discovery platform based in Antwerp.

◆ What sets it apart

Sightera uniquely integrates complex patient-derived preclinical models (SPAR technology) with AI to generate small molecules optimized for specific patient populations, rather than relying on traditional single-target discovery.

◆ Sectors

healthtechdeeptechbiotechAI

◆ Business

ModelSaaS

CustomerPharmaceutical and biotechnology companies

◆ Notable

  • Raised €3 million in a pre-seed round led by Entourage, Anacura, and QBIC
  • Spin-off from the University of Antwerp and Antwerp University Hospital (UZA)
  • Advancing molecular-glue oncology program SIGHT001 toward a preclinical candidate

◆ Funding rounds

pre-seed$3.3M

20 Jul 2026

Led by Entourage Ventures, Anacura, Qbic Fund

Source ↗

◆ Explore the market

BiotechPre-SeedBelgium

◆ FAQ

What does Sightera Biosciences do?

Patient-derived AI drug discovery platform based in Antwerp.

Where is Sightera Biosciences based?

Sightera Biosciences is based in Antwerp, Belgium, founded in 2024.

How much has Sightera Biosciences raised?

Sightera Biosciences has raised $3.3M in tracked funding and is currently at the pre-seed stage.

Who has invested in Sightera Biosciences?

Investors in Sightera Biosciences include Entourage, Anacura and QBIC.